All Articles tagged non-valvular atrial fibrillation
- Cardiovascular Conditions
February 01, 2016 EDT Cost-effectiveness of rivaroxaban (20 mg/day) versus use of acenocoumarol (5 mg/day) for the treatment of patients with non-valvular atrial fibrillation (NVAF) at moderate to high risk for stroke.